News Conference News HFSA 2024 ‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF Michael O'Riordan October 03, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Conference News HFSA 2023 REBALANCE-HF Uncovers HFpEF Group That Responds to Splanchnic Nerve Ablation Todd Neale October 11, 2023
News Conference News HFSA 2023 Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis Todd Neale October 11, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News HFSA 2021 PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF Todd Neale September 13, 2021
News Conference News HFSA 2020 Splanchnic Nerve Ablation Improves HFpEF Symptoms, QoL in FIH Study L.A. McKeown October 12, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020